BIOA BioAge Labs, Inc.
6.210USD-0.80%Mkt Cap: 285.02M $P/E: —1d ago
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to iden…
Industry Peers
Drug Manufacturers - Specialty & Generic$64.13BUSDP/E 24.9
$59.16BUSD
$45.78BUSDP/E 65.4
$43.33BUSDP/E 56.1
$40.72BUSDP/E 18.9
$34.23BUSDP/E 59.2
$32.92BUSDP/E 19.1
$30.20BUSDP/E 12.0
$22.85BUSDP/E 19.1
$20.03BUSD
$14.06BUSDP/E 110.0
$14.36BUSDP/E 20.7
$12.68BUSDP/E 22.9
$11.26BUSD
$10.16BUSDP/E 27.7
$8.71BUSDP/E 19.4
$6.84BUSDP/E 40.1
$6.66BUSDP/E 11.8
$6.73BUSDP/E 105.6
$6.55BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates BioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of +10.77% and +172.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection? BIOA clocked its worst day since December 2024 on Friday, while GLUE booked its worst day ever. | ||